- A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis - - First medicine in the EU to treat the CFTR protein defect in patients who have one copy of the F508del mutation and one copy of one of 14 mutations that result in residual
-Third-quarter 2018 total CF product revenues of $783 million , a 42% increase compared to $550 million in the third quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&D and SG&A expense
If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for these young children LONDON --(BUSINESS WIRE)--Oct. 19, 2018-- Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal
- Phase 2 results of VX-659 and VX-445 triple combination regimens concurrently published in The New England Journal of Medicine - - Phase 3 ARRIVAL data support treating the underlying cause of cystic fibrosis with KALYDECO ® (ivacaftor) as early as six months of age - - Patient-reported outcomes
BOSTON --(BUSINESS WIRE)--Oct. 16, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
- First-of-its-kind contract with the Danish pharmaceutical and procurement organization, Amgros, is effective from today - - Vertex also announces reimbursement in Austria for ORKAMBI ® (lumacaftor/ivacaftor) to treat patients ages 6 through 11 with two copies of the F508del mutation - LONDON
BOSTON --(BUSINESS WIRE)--Sep. 11, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.m. ET . The audio portion of management’s remarks will be available live
-- Ms. Jensen to oversee global CSR efforts and lead The Vertex Foundation -- BOSTON --(BUSINESS WIRE)--Sep. 10, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Katharine Jensen has been appointed Head of Corporate Social Responsibility (CSR). In this role, Ms.
-Data expected in late 2018 from Phase 3 studies of VX-659, tezacaftor and ivacaftor in people with one F508del mutation and one minimal function mutation and in people with two F508del mutations- -Enrollment of two Phase 3 studies of VX-445 in triple combination with tezacaftor and ivacaftor
- Approximately 1,300 patients in Australia join the thousands of patients worldwide who already have access to lumacaftor/ivacaftor - - A pathway to access for future Vertex CF medicine, tezacaftor/ivacaftor, has also been established - LONDON --(BUSINESS WIRE)--Sep.
Multi-year collaboration combines expertise in genomics, machine learning and drug discovery to identify novel targets for innovative medicines BOSTON & OXFORD, United Kingdom --(BUSINESS WIRE)--Aug. 30, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a
– Ludovic Fenaux to lead Vertex’s expanding International organization – – Simon Bedson announces retirement – LONDON --(BUSINESS WIRE)--Aug. 23, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ludovic Fenaux has been appointed Senior Vice President, International
- PBAC recommendation moves approximately 1,300 patients in Australia closer to access to lumacaftor/ivacaftor and Vertex is now working with the Australian Government to finalize a reimbursement agreement as soon as possible - LONDON --(BUSINESS WIRE)--Aug.
-- Boston Public High School Students Nora Nguyen and Sonny Mei Receive Vertex Science Leaders Scholarship to Pursue STEAM Degrees at UMass -- BOSTON --(BUSINESS WIRE)--Aug. 16, 2018-- Vertex today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride
- Approximately 1,300 people in the U.S. ages 2 through 5 years have two copies of the F508del mutation, the most common genetic form of the disease - BOSTON --(BUSINESS WIRE)--Aug. 7, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.
If approved, SYMKEVI ® (tezacaftor/ivacaftor) will be Vertex’s third medicine to treat the CFTR protein defect in patients with cystic fibrosis – a rare life-shortening disease LONDON --(BUSINESS WIRE)--Jul. 27, 2018-- Vertex Pharmaceuticals (Europe) Limited , today announced that the European
-Second-quarter 2018 total CF product revenues of $750 million , a 46% increase compared to $514 million in the second quarter of 2017- -Company increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&D and SG&A expense
BOSTON --(BUSINESS WIRE)--Jul. 12, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
-SYMDEKO is Vertex’s third medicine to treat the underlying cause of CF- -Approximately 2,000 people in Canada are ages 12 and older and have two copies of the F508del mutation or at least one mutation in the CF gene that is responsive to treatment with SYMDEKO- BOSTON --(BUSINESS WIRE)--Jun.
BOSTON --(BUSINESS WIRE)--Jun. 21, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year’s Warren Alpert Foundation Prize for “transformative discoveries in the fields of genetics,
BOSTON --(BUSINESS WIRE)--Jun. 18, 2018-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the opening of its new 170,000 square foot research facility in Torrey Pines , San Diego . The new site represents a significant expansion of the Company’s research presence in the area, and
- The agreement allows for reimbursement of ORKAMBI for people with cystic fibrosis who have two copies of the F508del mutation from July 1 - - A framework for assessment and access to our future cystic fibrosis medicines is included as part of the agreement - LONDON --(BUSINESS WIRE)--Jun.
BOSTON --(BUSINESS WIRE)--Jun. 14, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex employees and The Vertex Foundation have together donated over $1 million through the Company’s new dollar-for-dollar matching gift program.
- Data from KALYDECO ® (ivacaftor) studies show the potential to modify the long-term progression of the disease - - Interim analysis of the ongoing extension study of tezacaftor/ivacaftor combination (approved in the U.S. as SYMDEKO TM ) continues to demonstrate consistent safety and sustained
BOSTON --(BUSINESS WIRE)--Jun. 6, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Wednesday, June 13, 2018 at 5:40 p.m. ET ( 2:40 p.m. PT ). The audio portion of management’s remarks will be
BOSTON and ZUG, Switzerland and CAMBRIDGE, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug
All in for CF Scholarship Program Doubles to Help 80 Recipients Pursue Higher Education BOSTON --(BUSINESS WIRE)--May 1, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the recipients of scholarships as part of its second All in for CF Scholarship program.
-First-quarter 2018 total CF product revenues of $638 million , a 33% increase compared to $481 million in the first quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.65 to $2.80 billion and combined non-GAAP R&D and SG&A expense guidance of $1.50 to $1.55
-VX-445 triple combination regimen is the second of two different triple combination regimens to enter Phase 3 development in 2018- -Phase 3 study in approximately 360 patients with one F508del mutation and one minimal function mutation designed to support New Drug Application based on 4-week
BOSTON --(BUSINESS WIRE)--Apr. 17, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2018 financial results on Thursday, April 26, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
BOSTON --(BUSINESS WIRE)--Mar. 29, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018 , and will report to Michael J.
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018 , and will report to Michael J.
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Tuesday, March 13, 2018 at 12:00 p.m. ET . The audio portion of management's remarks will be available live through Vertex's website,
-Global Phase 3 study to enroll approximately 100 patients with the most common genetic form of the disease- -Phase 2 data showed mean absolute improvement in ppFEV 1 of 9.7 percentage points when VX-659 was added in people with CF who have two F508del mutations who were already receiving
- Jeffrey Chodakewitz , M.D., to retire and serve as senior advisor through early 2019- - Dr. Kewalramani to become CMO and Executive Vice President, Global Medicines Development and Medical Affairs, on April 1, 2018 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)
-Global Phase 3 study to enroll 360 patients with one F508del mutation and one minimal function mutation- -Study designed to support submission of New Drug Application in the U.S. based on 4-week primary efficacy endpoint and 12-week safety data- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals
-VX-150 was generally well tolerated and showed statistically significant relief of acute pain compared to placebo; study included an active reference arm of the opioid pain medicine hydrocodone+acetaminophen to support evaluation of VX-150 treatment effect- -Phase 2 study in acute pain is the
- SYMDEKO is Vertex's third medicine to treat the underlying cause of CF - - SYMDEKO to begin shipping to pharmacies this week - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved SYMDEKO ™
- Phase 2 data showed mean absolute improvements in ppFEV 1 of up to 13.3 and 13.8 percentage points for VX-659 and VX-445, respectively, in triple combination with tezacaftor and ivacaftor in people with CF who have one F508del mutation and one minimal function mutation (F508del/Min); triple
-Total 2017 CF product revenues of $2.17 billion , a 29% increase compared to $1.68 billion in 2016; 2017 KALYDECO revenues of $845 million and 2017 ORKAMBI revenues of $1.32 billion - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated
- In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - - Existing reimbursement agreements in countries like Ireland will enable rapid access to ORKAMBI; country-by-country reimbursement processes will now begin in other countries- LONDON
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:30 p.m. ET ( 9:30 a.m. PT ). The audio portion of management's remarks can be accessed live through
-Vertex selects CTX001 as first gene edited treatment to be developed as part of collaboration with CRISPR Therapeutics - -Clinical Trial Application for CTX001 submitted in Europe to support initiation of Phase 1/2 clinical study in β-thalassemia in 2018- -Preclinical data for CTX001 presented
-Study met primary safety endpoint and showed improvements across multiple endpoints, including measures of pancreatic function- -Potential to modify the course of CF in children as young as one year of age- -Results support FDA and EMA filings in the first quarter of 2018- BOSTON --(BUSINESS
- In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Union Committee for Medicinal Products for Human Use (CHMP) issued a positive
- Data from ongoing extension study of ORKAMBI ® (lumacaftor/ivacaftor) in children ages 6-11 and real-world KALYDECO ® (ivacaftor) data demonstrate long-term safety and other benefits of these medicines - - New data from ongoing extension study of tezacaftor/ivacaftor combination demonstrate
- Data showed significant improvements in lung function (ppFEV 1 ) with a favorable safety profile across multiple patient groups - - Tezacaftor/ivacaftor currently under review by the FDA and EMA; FDA Priority Review action date of February 28, 2018 - BOSTON --(BUSINESS WIRE)-- Vertex
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 10:35 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com